YORK, Sept. 7, 2022 /CNW/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or
"MindMed"), a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders, today announced
that it will participate virtually at the H.C. Wainwright 24th
Annual Global Investment Conference, and its presentation will be
available beginning at 7:00 a.m. ET
on September 12, 2022.
For details or to register to attend please visit
https://hcwevents.com/annualconference/. A replay of the webcast
will be available in the "News & Media" section of MindMed's
MindMed is a clinical stage biopharmaceutical company developing
novel products to treat brain health disorders. Our mission is to
be the global leader in the development and delivery of treatments
that unlock new opportunities to improve patient outcomes. We are
developing a pipeline of innovative drug candidates, with and
without acute perceptual effects, targeting the serotonin, dopamine
and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
For Media: email@example.com
For Investors: firstname.lastname@example.org
View original content to download
SOURCE Mind Medicine (MindMed) Inc.